-
Mashup Score: 21
Our findings suggested that rezivertinib is a potential choice for patients with EGFR-mutated locally advanced or metastatic NSCLC as first-line therapy, owing to the superior overall efficacy and subgroup progression-free survival compared with gefitinib in targeted patients. No new safety signals were identified.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24
/PRNewswire/ — Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the REZILIENT1 trial, a Phase 1/2…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet-
The Phase 2b REZILIENT1 study of zipalertinib (CLN-081/TAS6417) met its primary endpoint of response rate in patients with #EGFR exon 20 insertion mutation NSCLC. https://t.co/aFaQllG0x2
-
-
Mashup Score: 93
PURPOSEMobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Phase III EXCLAIM-2 trial of 1L mobocertinib vs chemotherapy in #EGFR exon 20 NSCLC @JCO_ASCO. Negative trial: PFS 9.6m in both arms (HR 1.04). RR 32% with mobocertinib and 30% with chemo. Mobocertinib also had 20% G3+ diarrhea. PAPILLON remains standard. https://t.co/UmNpXAUimv
-
-
Mashup Score: 75Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study - 9 day(s) ago
Amivantamab, an EGFR–MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced non-small cell lung cancer (NSCLC) as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related reactions (IRR) rate.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Phase 2 SKIPPirr study now @JTOonline: premedication regimen of oral dexamethasone 8mg BID on C1D-2, C1D-1, and morning of C1D1 (5 doses) when given before amivantamab for #EGFR NSCLC reduced risk of infusion reactions (22.5% vs 67.4% historically). https://t.co/GzejLa4vtV
-
-
Mashup Score: 84
Osimertinib is the first-line treatment for patients with non-small cell lung cancer (NSCLC) who have EGFR mutations and favorable performance status (PS). Despite increasing clinical data on osimertinib, evidence in patients with an impaired PS remains limited. Therefore, a multicenter phase II trial (OPEN/TORG2040) was conducted to evaluate the efficacy and safety of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor PS.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Phase II study of osimertinib in pts with #EGFR NSCLC and PS 2-4 (OPEN/TORG2040) @JTOonline (n=30). Here, RR 63.3%, DCR 93.3%, PS improvement in 63.3% with improvements in QoL. PFS 8m, OS 25.4m. Six pts (20%) developed ILD. https://t.co/NjkWHnqN55
-
-
Mashup Score: 132Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC | NEJM - 1 month(s) ago
Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal g…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Results from MARIPOSA now @NEJM - phase III trial of first-line amivantamab (EGFR-MET bispecific antibody) plus lazertinib (3G EGFR TKI) vs osimertinib in #EGFR mutant NSCLC. Ami/lazer superior to osimertinib with PFS 23.7m vs 16.6m (HR 0.70). https://t.co/rkWerM0m9u
-
-
Mashup Score: 90Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA) - 1 month(s) ago
Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Perioperative osimertinib for resectable #EGFR NSCLC in the single institution NORA trial @JTOonline from @jii_bum_lee et al. After 56d of neoadjuvant osimertinib, RR 44%, MPR 24%, pCR rate 0%. mDFS not yet reached after 31m. https://t.co/sfw28X6yYZ
-
-
Mashup Score: 30Seminal Trials: IPASS for EGFR NSCLC | IASLC - 2 month(s) ago
In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, …
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet-
In this episode of the @IASLC podcast, Lung Cancer Considered, Dr. @NarjustFlorezMD and I interviewed Dr. @TonyMok9 about the seminal IPASS trial in #EGFR NSCLC and the evolution of lung cancer research and treatment in general. https://t.co/X1U9cEi9j0
-
-
Mashup Score: 54Neratinib Efficacy in Patients with EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings from the SUMMIT Basket Trial - 2 month(s) ago
Estimates for the prevalence of mutations in the epidermal growth factor receptor (EGFR) gene range from 7% to 23% of patients with non-small-cell lung cancer (NSCLC).1 Two mutations, exon 19 deletions and the L858R substitution in exon 21, account for approximately 85% of all EGFR mutations in NSCLC; the remainder are termed rare mutations and include those occurring on exons 18–21.2
Source: www.clinical-lung-cancer.comCategories: General Medicine News, Hem/OncsTweet-
Neratinib for #EGFR exon 18 mutant NSCLC @ClinicalLung. In 31 pts, RR at 8 weeks was 19%, ORR 32% with mPFS 5.8m. Main toxicity was diarrhea (10% G3). Some activity here - but hoping agents in development have wider therapeutic window. https://t.co/Qty5abfdoH
-
-
Mashup Score: 85RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC - 2 month(s) ago
RELAY, a global double-blind, placebo-controlled Phase 3 study (NCT02411448) demonstrated statistically significant improvement in progression-free survival (PFS; primary endpoint) for ramucirumab (RAM)+erlotinib (ERL) in patients with untreated EGFR-mutated metastatic NSCLC: HR 0.59 (95%CI: 0.46–0.76, p<0.0001; median [m]PFS 19.4 versus 12.4 months). Here, we report final overall survival (OS; secondary endpoint) outcomes for the intention-to-treat (ITT) population.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Final OS results from RELAY (1L erlotinib +/- ramucirumab in #EGFR NSCLC) now @JTOonline. FDA approved based on PFS benefit. After 45m f/u, no OS difference (51.1m vs 46.0m, HR 0.98). Over 80% received 2L therapy (osimertinib use similar in both arms). https://t.co/RkZPRFuoOI
-
Results from Chinese phase III REZOR trial @LancetRespirMed - first line rezivertinib vs gefitinib for #EGFR NSCLC. Rezivertinib had better PFS (19.3m vs 9.6m, HR 0.48), similar rates of TRAEs. Unlikely to have impact unless it offers a cost advantage. https://t.co/OjD8reMVCt